Uterine cancer is the formation of tumors in tissues of uterus of women and is mostly caused to the women of age between 42–50 years. Cause of uterine cancer is unknown and if the cancer is detected in the late stage, it is hard to cure. Uterine cancer starts in the lining of uterus called endometrium. There are 4 types of uterine cancers including endometrial adenocarcinoma, adenosquamous carcinoma, papillary serous carcinoma, and uterine sarcoma. Rare types of uterine cancers that start in the muscle of uterus include endometrial stromal sarcoma, leiomyosarcoma, and undifferentiated sarcoma.
Increase in the prevalence of uterine cancer in the developed and developing region and growing geriatric population across the globe are the major factors driving the global uterine cancer market growth. According to the Centers for Disease Control & Prevention, prevalence of uterine cancer has increased by 12% during 1999–2015 in the U.S. Moreover, in 2016, more than 10,733 uterine cancer deaths were recorded in the U.S.
However, lack of advanced diagnostics center in the developing regions of the world including Latin America and Africa is expected to restrain the market over the forecast period 2019–2026. Other factors such as lack of awareness and poor healthcare infrastructure and low healthcare expenditure are anticipated to hamper the growth further.
The global uterine cancer market is segmented on the basis of type, treatment, end user, and region.
Based on type, the global uterine cancer market is segmented into endometrial adenocarcinoma, adenosquamous carcinoma, papillary serous carcinoma, and uterine sarcoma. Amongst type, adenosquamous carcinoma is expected to grow at a steady rate.
Based on treatment, the market is segmented into diagnosis, therapeutic treatment, and surgery. Diagnosis is further segmented into Pelvic examination, endometrial biopsy, transvaginal ultrasound, computed tomography (CT or CAT) scan, and magnetic resonance imaging (MRI). Therapeutic treatment is segregated into radiation therapy, chemotherapy, and hormone therapy. Surgery is further divided into hysterectomy and lymphadenectomy.
On the basis of end user, the market is segmented into hospitals, diagnostic centers, drug stores, online pharmacies, and other end users. Amongst end user, drug stores and online pharmacies are expected to grow at faster CAGR owing to ongoing research and development for better treatment options for treating uterine cancer.
In terms of region, the global uterine cancer market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa (LAMEA).
Got questions about your regional growth of
uterine cancer market?
Just drop us a line or call on +1 646 480 7505
North America is expected to account for largest share of the market owing to the high prevalence of uterine cancer in the region. According to the national cancer institute, over 63,230 cases of uterine cancer were registered in 2018 in the U.S.
Europe is expected to account for significant share of the global uterine cancer market owing to the presence of global major players in the region. Ongoing research and development regarding early diagnosis of the uterine cancer is expected to boost the market growth during the forecast period 2019–2026.
Asia Pacific uterine cancer market is forecasted to experience the fastest growth during the forecast period 2019–2026. Growth of Asia Pacific market is attributed to the constantly growing geriatric population and high prevalence of uterine cancer in the region.
Some of the major players of the global uterine cancer market are Novartis AG, Merck & Company, Inc., R-Pharm-US LLC., Actiza Pharmaceutical Private Limited, Pfizer Inc., United Biotech Pvt Ltd, Bristol-Myers Squibb Company, Elder Pharmaceuticals Ltd, Par Pharmaceutical Companies, Inc., and AstraZeneca Plc.
By End User